CGT Catapult establishes Technology Advisory Board led by chair Phil Vanek
CGT Catapult establishes Technology Advisory Board led by chair Phil Vanek
Publish Date: 2026-02-20 08:03:00
Source Domain: pmlive.com
Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has established a Technology Advisory Board to provide independent, strategic guidance. The board will support the CGT Catapult in identifying and removing barriers to the widespread adoption of advanced therapies.
The remit of the board will encompass areas including: data and digital; manufacturing and supply technology; product characterisation and testing; and novel patient treatment pathways. The board will identify opportunities and challenges arising from new technologies, as well as potential roadblocks to their widespread use.
The board is made up of advanced therapy experts from across academia, industry and regulation:
- Chair – Dr Phil Vanek, Founder, Redline Bioadvisors and Chief Commercialisation Officer, International Society for Cell & Gene Therapy (ISCT)
- Dr Deborah Hursh, Consultant and former FDA Senior Investigator
- John Lunger, life science executive and strategic advisor
- Professor Masahiro Kino-oka, Professor in Department of Biotechnology, The University of Osaka
- Dr James McCafferty, Chief Information Officer, Wellcome Sanger Institute
- Ian Rees, Unit Manager Inspectorate Strategy and Innovation, Medicines and Healthcare Products Regulatory Agency (MHRA)
- Professor Susan Rosser, Director of the UK Centre for Mammalian Synthetic Biology and Co-director of the Edinburgh Genome Foundry, University of Edinburgh.
In addition, from CGT Catapult, the board includes:
- Dr Jim Faulkner, Chair of the Board
- Dr Nicole Mather, Non-Executive Director
- Dr Jacqueline Barry, Chief Clinical Officer
- Dr Stephen Ward, Chief Technology Officer.
Dr Phil Vanek, Chair of the Technology Advisory Board, said: “CGT Catapult has played a critical role in shaping the advanced therapy landscape for more than a decade, and I’m…
